Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Synthetic Anti-infective Drugs >  Quinolones >  rosoxacin

rosoxacin

Basic information Safety Supplier Related

rosoxacin Basic information

Product Name:
rosoxacin
Synonyms:
  • 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid
  • Acrosoxacin
  • PD-107522
  • Win-35213
  • 1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid
  • 1-Ethyl-4-oxo-7-(4-pyridyl)-1,4-dihydroquinoline-3-carboxylic Acid
  • rosoxacin
  • 3-Quinolinecarboxylicacid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-
CAS:
40034-42-2
MF:
C17H14N2O3
MW:
294.3
EINECS:
254-758-4
Mol File:
40034-42-2.mol
More
Less

rosoxacin Chemical Properties

Melting point:
290°
Boiling point:
500.8±50.0 °C(Predicted)
Density 
1.317±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMF (Very Slightly)
form 
Solid
pka
6.48±0.41(Predicted)
color 
Light Beige to Beige
More
Less

rosoxacin Usage And Synthesis

Uses

Antibacterial.

Definition

ChEBI: A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by an ethyl group at position 1 and by a pyridin-4-yl group at position 7. An antibacterial drug, active against Neisseria gonorrhoeae, it has be n used for treating urinary tract infections and certain sexually transmitted diseases.

brand name

Roxadyl (Sterling Winthrop).

Pharmacokinetics

A single oral dose of 300 mg produces a mean peak plasma concentration of 4–5 mg/L at about 2–4 h, with an apparent elimination half-life of about 6 h. Elimination in the urine is partly as the N-oxide metabolite and the glucuronide of this metabolite.
Side effects are those common to quinolones, notably gastrointestinal tract and CNS disturbances. About 50% of patients treated with single oral doses of 100–400 mg developed dizziness, drowsiness, altered visual perception and other CNS effects.
It is effective as single-dose treatment of patients with urethral and anorectal gonorrhea, but coexistent C. trachomatis infection is not eliminated from most patients and postgonococcal urethritis develops in up to 30%.

rosoxacinSupplier

Accela ChemBio Co.,Ltd.
Tel
021-50795510 4000665055
Email
sales@accelachem.com
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com
DebyeTec.com Inc.
Tel
18086626237 18086626237
Email
sales@debyesci.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com